Abstract 19384: Favorable Association Between a Mediterranean Dietary Pattern and Cardiovascular Risk Factors in Patients with Stable Coronary Heart Disease in the STABILITY Study
Introduction: A ‘Mediterranean’ dietary (MD) pattern has been associated with lower cardiovascular mortality, but the reasons for benefit are uncertain.
Hypothesis: Greater adherence to a MD pattern is associated with more favorable cardiovascular risk factors.
Methods: Associations between a MD pattern and cardiovascular risk factors were evaluated at the baseline assessment in 15,482 (97.8%) patients with chronic coronary heart disease from 39 countries who participated in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY (STABILITY) trial. From a food frequency questionnaire a Mediterranean Diet Score (MDS) was calculated by
assigning points for more consumption of whole grains, fruits and vegetables, legumes, fish and alcohol, and for less consumption of meat (0 to 4 points in each food category). Cardiovascular risk factors at baseline are reported by approximate quartiles of MDS.
Results: See table. For all risk factors p was <0.0001 for differences by MDS group.
Conclusions: In a global population of patients with stable CHD greater adherence to a MD pattern was associated with less obesity, less hypertension, improved glucose tolerance and less inflammation.
Author Disclosures: R.A. Stewart: Research Grant; Significant; GlaxoSmithKline. Honoraria; Modest; Pfizer. L. Wallentin: Research Grant; Modest; Merck & Co, Boehringer Ingelheim. Research Grant; Significant; AstraZeneca, GlaxoSmithKline, Bistol-Myers Squibb/Pfizer. Honoraria; Modest; GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Bristol-Myers Squibb/Pfizer. Consultant/Advisory Board; Modest; GlaxoSmithKline, Abbott, Merck & Co, Regado Biosciences, Athera Biotechnologies, Boehringer Ingelheim, Bristol-Myers Squibb/Pfizer, AstraZeneca. Other; Modest; Lecture fees, AstraZeneca, Lecture fees, Boehringer Ingelheim, Lecture fees, Bristol-Myers Squibb/Pfizer, Travel support, AstraZeneca, Travel support, Bristol-Myers Squibb/Pfizer. J. Benatar: Honoraria; Modest; National Lipid association. N. Danchin: Research Grant; Significant; AstraZeneca, Daiichi-Sankyo, Eli Lilly, GlaxoSmithKline, MSD, Novartis, Sanofi. Speakers Bureau; Modest; Bayer, Boehringer Ingelheim, Eli Lilly, MSD, Novo-Nordisk, Pfizer, Sanofi, Servier, The Medicines Company. Speakers Bureau; Significant; AstraZeneca. Consultant/Advisory Board; Modest; Amgen, AstraZeneca, Bayer, Eli Lilly, GlaxoSmithKline, MSD, Novo-Nordisk, Roche, Sanofi. Consultant/Advisory Board; Significant; Servier. E. Hagström: Honoraria; Significant; Sanofi. R.A. Harrington: Research Grant; Significant; GlaxoSmithKline. C. Held: Research Grant; Modest; Bristol-Myers Squibb, Roche, AstraZeneca. Research Grant; Significant; GlaxoSmithKline, Merck. Speakers Bureau; Modest; AstraZeneca. S. Husted: Research Grant; Modest; GlaxoSmithKline, Pfizer. Honoraria; Modest; AstraZeneca. Consultant/Advisory Board; Modest; AstraZeneca, Bristol-Myers Squibb, Pfizer, Bayer. E. Lonn: Research Grant; Significant; AstraZeneca, Bayer, Amgen, GlaxoSmithKline, Hoffmann La-Roche. Consultant/Advisory Board; Modest; Amgen, Sanofi. A. Stebbins: None. O. Vedin: None. D. Watson: Employment; Significant; GlaxoSmithKline. H.D. White: Research Grant; Modest; Sanofi-Aventis, Eli Lilly, The Medicines Company, NIH, Roche, MSD, AstraZeneca, GlaxoSmithKline, Daiichi Sankyo Pharma Development. Consultant/Advisory Board; Modest; AstraZeneca, MSD, Roche, Regado Bioscience.
- © 2014 by American Heart Association, Inc.